SDHB and cancer: Importantly, besides PCC/PGLs, SDH inactivation is increasingly observed in other neuroendocrine malignancies as well as in gastrointestinal neoplasms and renal cell carcinomas [3], and, thus, it is expected that it will acquire a more general clinical relevance in cancer pathogenesis.